Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report
<p>Abstract</p> <p>Introduction</p> <p>Soft tissue sarcomas are heterogeneous tumors that are difficult to treat. Up to 50 percent of patients develop metastatic disease and require systemic chemotherapy. Ifosfamide and doxorubicin are the two most active agents.</p&...
Main Authors: | Pedrinaci Irene Zarcos, Jurado José Miguel, Carrillo Josefa, Molina Mercedes Caba |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-12-01
|
Series: | Journal of Medical Case Reports |
Online Access: | http://www.jmedicalcasereports.com/content/6/1/424 |
Similar Items
-
Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
by: Hironari Tamiya, et al.
Published: (2020-01-01) -
Tumor Calcification: A New Response Pattern of Myxoid Liposarcoma to Trabectedin
by: Anthony Turpin, et al.
Published: (2014-03-01) -
Prognostic factors of metastatic myxoid liposarcoma
by: Yusuke Shinoda, et al.
Published: (2020-09-01) -
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
by: Sarah Uboldi, et al.
Published: (2012-01-01) -
Myxoid Liposarcoma- A case Report
by: Shubhangi Pawar, et al.
Published: (2016-06-01)